Ozempic And Wegovy May Reduce Inflammation As Well As Weight Loss

Do Ozempic and Wegovy reduce inflammation as well as support weight loss in Europe?Ozempic and Wegovy explained: semaglutide, GLP-1 receptor agonists, weight reduction, inflammatory markers (CRP), metabolic health, and prescribing criteria.In this episode, we examine emerging research on semaglutide’s potential anti-inflammatory effects and how doctors interpret these findings under EU medical guidance.You’ll learn:• How GLP-1 receptor agonists improve glucose regulation and reduce appetite• Why weight loss itself can lower systemic inflammation• The role of C-reactive protein (CRP) as an inflammatory marker• Current evidence on cardiovascular risk reduction• The difference between approved indications and ongoing research• Common side effects: nausea, vomiting, gastrointestinal discomfort• Red flag symptoms such as severe abdominal pain or persistent vomiting• Situations where treatment requests may be declined without meeting BMI or diabetes criteriaWe explain how doctors assess BMI, HbA1c, cardiovascular risk, lipid profile, kidney function, and overall metabolic health during an online consultation in the EU. While inflammation markers may improve with treatment, prescribing decisions are based on approved clinical indications.This episode reflects the clinical standards used by Mobi Doctor, where metabolic consultations are reviewed by a registered physician in line with EU prescribing guidance.Read the full guide and transcript here:https://www.mobidoctor.eu/blog/ozempic-and-wegovy-may-reduce-inflammation-as-well-as-weight-loss